Ptc Therapeutics, Inc. (PTCT) Stock Price & Analysis

Ptc Therapeutics, Inc. (PTCT) rose 3.96% to USD 73.68 as of June 10, 2026 at 00:42 UTC, according to Nexqual real-time market data.

PTCT last closed at USD 70.87; the session ranged USD 71.3–74.29 on volume of 1,851,508 shares. Market capitalization is $6.11B, with a 52-week range of USD 43.18–87.5 (NMS). Source: Nexqual, June 10, 2026 at 00:42 UTC.

Key Statistics (as of June 10, 2026 at 00:42 UTC)

Technical Analysis (PTCT)

Nexqual's technical model rates PTCT "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 00:42 UTC.

Analyst Ratings (PTCT)

Wall Street analysts rate PTCT "Buy" based on 14 analysts, with a mean price target of USD 93.93 (range USD 65–124), per Nexqual as of June 10, 2026 at 00:42 UTC.

Earnings (PTCT)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 00:42 UTC.

Financials & Fundamentals (PTCT)

Source: Nexqual, June 10, 2026 at 00:42 UTC.

Financial Health Score (PTCT)

Nexqual rates Ptc Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:42 UTC.

Ownership (PTCT)

Source: Nexqual, June 10, 2026 at 00:42 UTC.

Leadership (PTCT)

Ptc Therapeutics, Inc. is led by Matthew B. Klein F.A.C.S., M.D., M.S. (age 53), CEO & Director, per Nexqual as of June 10, 2026 at 00:42 UTC.

Major Backers & Investors (PTCT)

Notable institutional backers of Ptc Therapeutics, Inc. include RTW Investments LP, Janus Henderson Group PLC, Wellington Management, according to Nexqual as of June 10, 2026 at 00:42 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 00:42 UTC.

From Ptc Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)

Key Strengths & Strategy (as disclosed to the SEC)

• The patent portfolio includes patents and patent applications with claims including composition of matter, pharmaceutical formulation and methods of use of our commercial products including sepiapterin, the active ingredient in the formulated product Sephience, ataluren, the active ingredient in the formulated product Translarna, and risdiplam, the active ingredient in the formulated product Evrysdi.
• We seek to protect our proprietary technology and processes, in part, using confidentiality agreements with our employees, consultants, scientific advisors, contractors and collaborators.
• Intellectual Property Patents and trade secrets Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights.
• We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position.

Partnerships

• In addition, Akcea has granted to us a non-exclusive right and license, with the right to grant certain sublicenses, under Akcea's core intellectual property and manufacturing intellectual property to develop, manufacture and commercialize the Products in the PTC Territory and to manufacture the Products worldwide in accordance with a supply agreement with Akcea.
• In November 2024, we entered into a License and Collaboration Agreement with Novartis Pharmaceuticals Corporation, or Novartis, relating to our votoplam program, or the Novartis Agreement, which included related molecules.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:42 UTC. This page is informational and not investment advice.